[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1948643T3 - 3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)pyrrolidin-2-on-derivater som mellemprodukter i syntese af renininhibitorer - Google Patents

3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)pyrrolidin-2-on-derivater som mellemprodukter i syntese af renininhibitorer

Info

Publication number
DK1948643T3
DK1948643T3 DK06828821.6T DK06828821T DK1948643T3 DK 1948643 T3 DK1948643 T3 DK 1948643T3 DK 06828821 T DK06828821 T DK 06828821T DK 1948643 T3 DK1948643 T3 DK 1948643T3
Authority
DK
Denmark
Prior art keywords
alkyl
pyrrolidin
intermediates
oxo
tetrahydrofuran
Prior art date
Application number
DK06828821.6T
Other languages
English (en)
Inventor
Gottfried Sedelmeier
Dominique Grimler
Murat Acemoglu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35451886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1948643(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1948643T3 publication Critical patent/DK1948643T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
DK06828821.6T 2005-10-17 2006-10-16 3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)pyrrolidin-2-on-derivater som mellemprodukter i syntese af renininhibitorer DK1948643T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0521083.6A GB0521083D0 (en) 2005-10-17 2005-10-17 Organic compounds
PCT/EP2006/009970 WO2007045420A2 (en) 2005-10-17 2006-10-16 3-alkyl-5- (4-alkyl-5-oxo-tetrahydrofutran-2-yl) pyrrolidin-2-one derivatives as intermediates in the synthesis of renin inhibitors

Publications (1)

Publication Number Publication Date
DK1948643T3 true DK1948643T3 (da) 2013-09-08

Family

ID=35451886

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06828821.6T DK1948643T3 (da) 2005-10-17 2006-10-16 3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)pyrrolidin-2-on-derivater som mellemprodukter i syntese af renininhibitorer

Country Status (30)

Country Link
US (2) US7772405B2 (da)
EP (1) EP1948643B1 (da)
JP (3) JP5356031B2 (da)
KR (1) KR101294432B1 (da)
CN (2) CN103121995B (da)
AR (1) AR058089A1 (da)
AU (1) AU2006303489B2 (da)
BR (1) BRPI0617492A2 (da)
CA (2) CA2625034C (da)
CY (1) CY1114308T1 (da)
DK (1) DK1948643T3 (da)
EC (1) ECSP088368A (da)
ES (1) ES2427098T3 (da)
GB (1) GB0521083D0 (da)
HK (1) HK1120509A1 (da)
HR (1) HRP20130793T1 (da)
IL (1) IL190330A (da)
JO (1) JO2926B1 (da)
MY (1) MY145466A (da)
NO (1) NO342854B1 (da)
NZ (1) NZ567042A (da)
PE (2) PE20070792A1 (da)
PL (1) PL1948643T3 (da)
PT (1) PT1948643E (da)
RU (1) RU2432354C2 (da)
SI (1) SI1948643T1 (da)
TN (1) TNSN08170A1 (da)
TW (1) TWI395733B (da)
WO (1) WO2007045420A2 (da)
ZA (1) ZA200802632B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
DE102005052195A1 (de) * 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
MX2009010699A (es) * 2007-04-03 2010-03-10 Novartis Ag Nuevos metodos.
KR20100041772A (ko) * 2007-06-19 2010-04-22 노파르티스 아게 알리스키렌과 같은 레닌 억제제의 중간체의 합성 방법
DE102007049039A1 (de) * 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
SI2189442T1 (sl) * 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
MX2012001850A (es) 2009-08-11 2012-03-07 Massachusetts Inst Technology Abertura de anillo de lactonas y lactamas.
US8203005B2 (en) * 2009-10-29 2012-06-19 Carbo Design Llc Manufacturing process for enantiomerically pure 8-aryloctanoic acids as Aliskiren
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
CN101774986B (zh) 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102241650B (zh) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
CN102485722B (zh) * 2010-12-06 2014-05-07 博瑞生物医药技术(苏州)有限公司 阿利克仑、其中间体和药用盐及制备方法
CN102775393B (zh) * 2011-05-09 2014-08-27 上海现代制药股份有限公司 一种药物中间体的制备方法
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
CN102746182B (zh) * 2012-07-27 2014-09-03 浙江普洛医药科技有限公司 一种阿利克伦的制备方法
CN103059012B (zh) * 2013-01-30 2016-06-22 浙江海翔药业股份有限公司 1,8-二羰基-4,5-环氧化合物及其制备方法
CN106220528B (zh) * 2014-02-28 2018-05-08 华润双鹤药业股份有限公司 阿利吉仑的4-位差向异构体、其制备方法及用途
CN105294612A (zh) * 2014-06-05 2016-02-03 山东威智医药工业有限公司 阿利克仑中间体及其制备方法和应用
US10087190B1 (en) * 2017-04-24 2018-10-02 Purdue Research Foundation Lactones
CN114315749B (zh) * 2021-12-13 2024-04-26 湖南华腾医药有限公司 一种连续流微反应器合成阿利克仑中间体的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
ES2312346T3 (es) 1999-07-29 2009-03-01 Speedel Pharma Ag Produccion de 2,7-dialquil-4-hidroxi-5-amino-8-aril-octanoilamidas n-sustituidas.
FR2801051B1 (fr) * 1999-11-17 2001-12-14 Adir Nouveaux composes aminopyrroline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6310904B1 (en) 2000-05-31 2001-10-30 Honeywell International, Inc. Measurement method to facilitate production of self-aligning laser gyroscope block
ES2274847T3 (es) 2000-12-14 2007-06-01 Speedel Pharma Ag Proceso para preparar ariloctanoil-amidas.
DE50207212D1 (de) * 2001-09-07 2006-07-27 Basf Ag Verfahren zur herstellung von 2-pyrrolidon
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
CN102260188A (zh) * 2003-11-26 2011-11-30 诺瓦提斯公司 有机化合物
AU2004298486A1 (en) * 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
WO2005090305A1 (en) * 2004-03-19 2005-09-29 Speedel Experimenta Ag 5-amino-4-hydroxy-7-(1h-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension
EP1582523A1 (en) * 2004-04-02 2005-10-05 Ludwig-Maximilians-Universität München Method of preparing organomagnesium compounds
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
ZA200802632B (en) 2009-04-29
RU2008119276A (ru) 2009-11-27
ES2427098T3 (es) 2013-10-28
NO342854B1 (no) 2018-08-20
BRPI0617492A2 (pt) 2011-07-26
TWI395733B (zh) 2013-05-11
AU2006303489A1 (en) 2007-04-26
AU2006303489B2 (en) 2011-04-07
CA2625034C (en) 2014-08-19
PE20120581A1 (es) 2012-06-08
JP2013032369A (ja) 2013-02-14
ECSP088368A (es) 2008-05-30
RU2432354C2 (ru) 2011-10-27
NZ567042A (en) 2012-02-24
KR101294432B1 (ko) 2013-08-07
KR20080057285A (ko) 2008-06-24
TW200800965A (en) 2008-01-01
CY1114308T1 (el) 2016-08-31
AR058089A1 (es) 2008-01-23
JP5792139B2 (ja) 2015-10-07
PT1948643E (pt) 2013-09-05
US20080262246A1 (en) 2008-10-23
IL190330A0 (en) 2009-09-22
IL190330A (en) 2013-12-31
JP2014196312A (ja) 2014-10-16
US20100267965A1 (en) 2010-10-21
US7772405B2 (en) 2010-08-10
CN101111493B (zh) 2013-02-13
TNSN08170A1 (en) 2009-10-30
GB0521083D0 (en) 2005-11-23
SI1948643T1 (sl) 2013-10-30
WO2007045420A3 (en) 2007-06-07
NO20082263L (no) 2008-07-07
EP1948643B1 (en) 2013-06-05
WO2007045420A2 (en) 2007-04-26
JP2009514808A (ja) 2009-04-09
MY145466A (en) 2012-02-15
CN101111493A (zh) 2008-01-23
PE20070792A1 (es) 2007-09-10
US8198465B2 (en) 2012-06-12
HRP20130793T1 (hr) 2013-09-30
EP1948643A2 (en) 2008-07-30
CA2829487A1 (en) 2007-04-26
HK1120509A1 (en) 2009-04-03
PL1948643T3 (pl) 2013-11-29
CN103121995B (zh) 2016-08-03
JO2926B1 (en) 2015-09-15
JP5356031B2 (ja) 2013-12-04
CA2625034A1 (en) 2007-04-26
CN103121995A (zh) 2013-05-29

Similar Documents

Publication Publication Date Title
DK1948643T3 (da) 3-Alkyl-5-(4-alkyl-5-oxo-tetrahydrofuran-2-yl)pyrrolidin-2-on-derivater som mellemprodukter i syntese af renininhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
CY2016028I2 (el) S-τριαζολυλ αλφα-μερκαπτοακετανιλιδες ως αναστολεις της αντιστροφης μεταγραφασης του ηιv
DK1981875T3 (da) Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
CY2016045I2 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK2139892T3 (da) Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
DK1962830T3 (da) Azaindolhæmmere af aurorakinaser.
DK1959951T3 (da) Heteroaryl-substituerede piperidinderivater som L-CPT1-inhibitorer
NO20076678L (no) Glutamataggrekanaseinhibitorer
DK1881976T3 (da) Substituerede amidderivater som proteinkinaseinhibitorer
DK1586319T3 (da) Thiadiazolidinoner som GSK-3-inhibitorer
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
NO20082514L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
DK1898903T3 (da) Inhibitorer af Akt-aktivitet
DK1848694T3 (da) Heterocykliske substituerede phenylmethanoner som inhibitorer af glycintransporter
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK2015754T3 (da) Anvendelse af dpp-iv-inhibitorer
DK1888582T3 (da) Imidazo- og triazolopyridiner som hæmmere af 11-beta-hydroxysteroid dehydrigenase
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
DK2364308T3 (da) Pyrazinforbindelser som inhibitorer af Phosphodiesterase 10
ATE487691T1 (de) Acetylenderivate